← All candidates
112 insider filings on record.
Gilbert Ray Cisneros, Jr.Small Business · Armed Servicestraded 15 May · filed 8 Jun · selfSold$1K–$15Kself15 May124d ago8 Jun100d ago
Julia LetlowEducation and Workforce · Appropriationstraded 12 Feb · filed 12 Mar · selfBought$1K–$15Kself12 Feb216d ago12 Mar188d ago112 filings on record.
REGNREGENERON PHARMACEUTICALS, INC.
NasdaqGS · Healthcare · $80.05B
$774.11
+0.06% today
112 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 59 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$80.05B
Float
95.8M
95% public
Short % float
Pro
Price / profit
19.2
Price / future profit
12.8
Price / sales
5.2
Congress
▸ Disclosures lag trades by 30–45 days.
3 disclosures12 mo
MemberTradeAmountOwnerTradedFiled
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
107 more transactions on Pro →Context
Wall St
$849.32 avg target
+9.7% vs today · 27 analysts · consensus Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
4 of 4 quarters beat
Q2 '26$14.29 act+$4.08
Q1 '26$9.47 act+$0.57
Q4 '25$11.44 act+$0.69
Q3 '25$11.83 act+$2.19
Coverage
Will Fianlimab-Libtayo Trial Misstatement Lawsuits Change Regeneron Pharmaceuticals' (REGN) Pipeline-Driven Narrative?Simply Wall St. · 1d agoNovo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?Motley Fool · 1d agoRegeneron Pharmaceuticals (REGN) Could Be 5% Undervalued Following Trial Lawsuit NewsSimply Wall St. · 1d ago
The file stays open
112 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice